UNSPSC 51111615: Glutathione

This classification denotes an antioxidant with the molecular formula C10H17N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GAN16C9B8O, chemically known as glycine, n-(n-l-gamma-glutamyl-l-cysteinyl)- but generally known as glutathione, which bears US NIH Compound Identifier 745. European Medicines Agency schedules Glutathione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13990MIG. World Health Organization schedules glutathione in its Anatomical Therapeutic Chemical (ATC) Classification.

As of Q4 2014, GLUTATHIONE remains the US FDA Preferred Term for this commodity. Glutathione bears US NLM identifiers UMLS ID C0017817 and NCI Concept Code C523. SMILES: C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N.

UNSPSC 51111615 Glutathione, a Commodity code, identifies a specific pharmaceutical ingredient that state and local health agencies procure for direct distribution, institutional use, or integration into pharmacy benefit programs. The single recent opportunity in the dataset—Texas Health and Human Services Commission's Request for Information No. HHS0017013, posted April 3, 2026—does not solicit glutathione directly but rather seeks vendor capabilities for a Therapeutic Pharmacy Initiative enabling direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. This RFI targets vendors with experience in direct contracting for self-insured employers and government health plans, negotiated net pricing models, and value-based or outcomes-based agreements. The procurement focuses on program design and vendor qualification rather than on any specific pharmaceutical product line, suggesting that glutathione procurement under this code may occur as part of a broader pharmaceutical supply or formulary initiative rather than as a standalone commodity solicitation.

The recent opportunity originates from Texas state government—specifically a state health agency—with no geographic spread across multiple jurisdictions evident in the available record. The RFI itself is exploratory in nature, designed to inform future formal procurement strategy before a full RFP is issued; no award value, budget range, or binding response timeline applies. State and local procurement activity under this Commodity code does not show sufficient recent opportunities to establish a clear pattern of current demand, issuing-body concentration, or geographic distribution. Firms evaluating this code should monitor Texas HHS for the anticipated formal RFP and consider whether their glutathione supply, direct-to-manufacturer relationships, or pharmacy benefit program capabilities align with the state's emerging direct-contracting model.